Skip to main content


  • Organization
    Vanderbilt University

  • Use Statement - Please enter your reason for creating an NCI Hub account.
    (not set)

  • Reason
    (not set)

  • Biography

    Positions and Employment

    1999 – 2001    Research and Teaching Assistant, Department of Biochemistry, College of Medicine, 
Korea University, Seoul, Korea (Advisor: Yun Gyu Park, MD, PhD)

    2001 – 2004    Public Health Doctor (in lieu of mandatory military service), 
Public Health Center of Yang-ju city, Korea

    2004 – 2008    Graduate Research Assistant, Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX (Advisor: Gary E. Gallick, PhD)

    2008 – 2012     Research Fellow, Department of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, MI (Advisor: Laurie K. McCauley, DDS, PhD)

    2012 –        Assistant Professor, Departments of Medicine (Clinical Pharmacology) and Cancer Biology, Vanderbilt University, Nashville, TN

    2012 –        Researcher, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN

    Other Experience and Professional Membership

    2008-        The American Association for Cancer Research

    2011-        The American Society for Bone and Mineral Research

    2011-        The International Bone and Mineral Society

    2012-        Editorial Board, Endocrinology and Metabolism

    2012-2013    Department of Defense Prostate Research Program Scientific Review Panels (Cell Biology)


    2007         Prostate Cancer Training Award (Pre-Doctoral), the U.S. Department of Defense

    2008        Graduate Student Research Award, M.D. Anderson Alumni and Faculty Association

    2009        Prostate Cancer Training Award (Post-Doctoral), the U.S. Department of Defense

    2011        Short Talk Presentation Award, the 11th Cancer-Induced Bone Disease Conference

    2011        Exploration-Hypothesis Development Award, the U.S. Department of Defense

    2012         Young Investigator Award, the American Society for Bone and Mineral Research

    C. Selected Peer-Reviewed Publications (total 22 publications)

    1.    Park SI, Shah AN, Zhang J, Gallick GE. Regulation of angiogenesis and vascular permeability by Src family kinases: Opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Targets. 2007 Sep;11(9):1207-17. Review. PMID: 17845146

    2.    Zhang J, Park SI, Artime MC, Summy JM, Shah AN, Bomser JA, Dorfleutner A, Flynn DC, Gallick GE. AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest. 2007 Oct;117(10):2962-73. PMCID: PMC1978423

    3.    Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007 Dec;14(12):3629-37. PMID: 17909916

    4.    Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008 May; 68(9):3323-33. PMID: 18451159

    5.    Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res. 2009 Jan; 335(1):249-59. Review. PMID: 18815812

    6.    Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the Src family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res. 2009 May; 69(9):3842-9. PMCID: PMC2709758

    7.    Park SI, Kim SJ, McCauley LK, Gallick GE. Preclinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol. 2010 Dec1; 51:14.15.1-14.15.27. PMCID: PMC3072580

    8.    Li X, Koh AJ, Wang Z, Soki FN, Park SI, Pienta KJ, McCauley LK. Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. J Bone Miner Res. 2011 Jan; 26(1):125-34. PMCID: PMC3179321

    9.    Li X, Liao J, Park SI, Koh AJ, Sadler WD, Pienta KJ, Rosol TJ, McCauley LK. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. Bone. 2011 Jun 1; 48(6):1354-61. PMCID: PMC3457787

    10.    Park SI, Soki FN, McCauley LK. Roles of Bone Marrow Cells in Skeletal Metastasis: No Longer Bystanders. Cancer Microenviron. 2011 Dec; 4(3):237-46. PMCID: PMC3234319

    11.    Park SI, McCauley LK. Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells.  Endocr Relat Cancer. 2012 May 3; 19(3):243-54. PMCID: PMC3593272

    12.    Park SI, Liao J, Berry JE, Li X, Koh AJ, Michalski MN, Eber MR, Soki FN, Sadler WD, Sud S, Tisdelle SM, Daignault SD, Nemeth JA, Snyder LA, Wronski TJ, Pienta KJ, McCauley LK.  Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res. 2012 May 15; 72(10):2522-32. PMCID: PMC3457788

    13.    Jung Y, Shiozawa Y, Wang J, McGregor N, Dai J, Park SI, Berry JE, Havens AM, Joseph J, Kim JK, Patel L, Carmeliet P, Daignault S, Keller ET, McCauley LK, Pienta KJ, Taichman RS.  Prevalence of prostate cancer metastasis following intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. Neoplasia. 2012 May; 14(5):429-439. PMCID: PMC3384430

    14.    Soki FN, Park SI, McCauley LK. The multifaceted actions of PTHrP in skeletal metastasis.  Future Oncol. 2012 Jul; 8(7):803-17. Review. PMCID: PMC3566558

    15.    Ding X, Park SI, McCauley LK, Wang CY. Signaling between TGF-beta and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. J Biol chem. 2013 Apr 12; 288(15):10241-53. PMCID: PMC3624408

    16.    Jin R, Sterling JA, Edwards JR, Degraff DJ, Lee C, Park SI, Matusik RJ. Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PLoS One. 2013; 8(4):e60983.  PMCID: PMC3618119

    17.    Park SI, Lee C, Sadler WD, Koh AJ, Jones J, Seo JW, Soki FN, Cho SW, Daignault SD, McCauley LK. Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res. 2013 Nov 15; 73(22):6574-83. PMCID: PMC3838921

    18.    Cho SW, Soki FN, Koh AJ, Eber M, Entezami P, Park SI, van Rooijen N, McCauley LK. Osteal macrophages support physiologic skeletal remodeling and anabolic actions of parathyroid hormone in bone. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):1545-50. PMCID: PMC3910564

    19.    Zhang H, Yu C, Dai J, Keller JM, Hua A, Sottnik JL, Shelley G, Hall CL, Park SI, Yao Z, Zhang J, McCauley LK, Keller ET. Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of beta-catenin activation of the DKK1 promoter in prostate cancer. Oncogene. 2014 May 8; 33(19):2464-77. PMCID: PMC4004708

    20.    Buenrostro D, Park SI, Sterling JA. Dissecting the role of bone marrow stromal cells on bone metastases. Biomed Res Int. 2014; 2014:875305. Review. PMID: 25054153 (=Co-Corresponding Authors)